AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with …
Over the last 12 months, insiders at AbbVie Inc. have bought $0 and sold $143.86M worth of AbbVie Inc. stock.
On average, over the past 5 years, insiders at AbbVie Inc. have bought $667,072 and sold $84.67M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750 shares for transaction amount of $51,750 was made by Durkin Brian L (VP, Controller) on 2020‑03‑30.
2024-12-16 | Sale | SVP, CONTROLLER | 1,800 0.0001% | $172.24 | $310,032 | +2.24% | ||
2024-08-05 | Sale | EXECUTIVE CHAIRMAN OF BOARD | 66,500 0.0038% | $186.52 | $12.4M | +4.92% | ||
2024-07-17 | Sale | EXECUTIVE CHAIRMAN OF BOARD | 282,845 0.016% | $175.00 | $49.5M | +9.47% | ||
2024-03-20 | Sale | EVP, CHIEF BUS/STRAT OFFICER | 21,082 0.0012% | $176.30 | $3.72M | +0.03% | ||
2024-03-18 | Sale | EVP, CHIEF COMMERCIAL OFFICER | 58,949 0.0033% | $178.79 | $10.54M | -1.20% | ||
2024-03-01 | Sale | EVP, CHIEF HR OFFICER | 75,680 0.0042% | $177.27 | $13.42M | -0.88% | ||
2024-02-29 | Sale | PRES & CHIEF OPERATING OFFICER | 68,879 0.0039% | $176.45 | $12.15M | +0.83% | ||
2024-02-29 | Sale | EVP, GC AND SECRETARY | 9,891 0.0006% | $177.39 | $1.75M | +0.83% | ||
2024-02-29 | Sale | SVP, CONTROLLER | 5,144 0.0003% | $176.65 | $908,688 | +0.83% | ||
2024-02-28 | Sale | CHAIRMAN OF THE BOARD AND CEO | 138,616 0.0078% | $177.27 | $24.57M | -0.41% | ||
2024-02-23 | Sale | EVP, GC AND SECRETARY | 13,753 0.0008% | $177.51 | $2.44M | -0.22% | ||
2024-02-23 | Sale | EVP, CHIEF FINANCIAL OFFICER | 14,140 0.0008% | $177.44 | $2.51M | -0.22% | ||
2024-02-21 | Sale | EVP, CHIEF OPERATIONS OFFICER | 52,870 0.003% | $173.71 | $9.18M | +1.46% | ||
2023-12-26 | Sale | EVP, CHIEF BUS/STRAT OFFICER | 2,912 0.0002% | $154.72 | $450,545 | +13.34% | ||
2023-08-01 | Sale | CHAIRMAN OF THE BOARD AND CEO | 60,000 0.0035% | $148.58 | $8.91M | +8.24% | ||
2023-07-31 | Sale | CHAIRMAN OF THE BOARD AND CEO | 18,500 0.0011% | $149.15 | $2.76M | +7.42% | ||
2023-04-25 | Sale | SVP, US COMMERCIAL OPERATIONS | 6,130 0.0003% | $165.00 | $1.01M | -8.43% | ||
2023-04-17 | Sale | SVP, US COMMERCIAL OPERATIONS | 7,499 0.0004% | $161.67 | $1.21M | -6.32% | ||
2023-04-03 | Sale | 15,002 0.0008% | $160.03 | $2.4M | -5.03% | |||
2023-04-03 | Sale | 3,520 0.0002% | $160.00 | $563,200 | -5.03% |
Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 60941 0.0034% | $175.58 | 1 | 8 | +37.99% |
Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 55903 0.0032% | $175.58 | 1 | 2 | +35.4% |
Schumacher Laura J | Vice Chairman | 213003 0.0121% | $175.58 | 1 | 14 | +27.78% |
CHASE WILLIAM J | EVP, Finance & Administration | 169552 0.0096% | $175.58 | 1 | 7 | +28.08% |
Gosebruch Henry O | EVP, Chief Strategy Officer | 41623 0.0024% | $175.58 | 1 | 6 | +30.67% |
The Vanguard Group | $31.03B | 9.65 | 170.38M | +6.22% | +$1.82B | 0.57 | |
BlackRock | $26.03B | 8.1 | 142.96M | -0.16% | -$40.72M | 0.57 | |
State Street | $14.2B | 4.42 | 77.97M | -0.29% | -$41.92M | 0.58 | |
JPMorgan Chase | $9.33B | 2.9 | 51.26M | -1.08% | -$102.03M | 0.83 | |
Capital International Investors | $8.76B | 2.72 | 48.1M | +6.91% | +$566.44M | 1.78 |